How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,625 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. Full Text available with Trip Pro

One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. This study compares 1-year intrauterine device (IUD) continuation among women presenting for emergency contraception (EC) and initiating the copper (Cu T380A) IUD or the levonorgestrel (LNG) 52 mg IUD plus 1.5 mg oral LNG.This cohort study enrolled 188 women who presented at a single family planning clinic in Utah between June 2013 and September 2014 and selected either (...) for 147 (84%) participants, 33 (22%) had requested removals, 13 (9%) had an expulsion and declined reinsertion, 3 (2%) had a pregnancy with their IUD in place and 98 (67%) were still using their device. Continuation rates did not differ by IUD type; 60% of Cu T380A IUD users and 70% of LNG 52 mg IUD plus oral LNG users were still using their device at 12 months (adjusted hazard ratio 0.72, 95% confidence interval 0.40-1.3).Two-thirds of women who chose IUD placement at the EC clinical encounter

2017 Contraception

162. Immediate postpartum intrauterine device and implant program outcomes: A prospective analysis. (Abstract)

Immediate postpartum intrauterine device and implant program outcomes: A prospective analysis. In-hospital placement of intrauterine devices and contraceptive implants following vaginal and cesarean delivery is increasingly popular and responds to maternal motivation for highly effective postpartum contraception. Immediate postpartum intrauterine device insertion is associated with higher expulsion than interval placement, but emerging evidence suggests that the levonorgestrel intrauterine (...) device may have a higher expulsion rate than the copper intrauterine device.This study evaluated in-hospital provision, expulsion, and 6-month continuation of immediate postpartum copper T380 intrauterine devices, levonorgestrel intrauterine devices, and contraceptive implants.We offered enrollment in this prospective observational trial to women presenting to the University of Utah labor and delivery unit from October 2013 through February 2016 who requested an intrauterine device or implant

2017 American Journal of Obstetrics and Gynecology

163. Continuation of copper and levonorgestrel intrauterine devices: A retrospective cohort study. Full Text available with Trip Pro

Continuation of copper and levonorgestrel intrauterine devices: A retrospective cohort study. Studies conflict on whether the duration of use of the copper intrauterine device is longer than that of the levonorgestrel intrauterine device, and whether women who continue using intrauterine devices differ from those who discontinue.We sought to assess continuation rates and performance of levonorgestrel intrauterine devices compared with copper intrauterine devices over a 5-year period.We (...) performed a retrospective cohort study of 1164 individuals who underwent intrauterine device placement at an urban academic medical center. The analysis focused on a comparison of continuation rates between those using levonorgestrel intrauterine device and copper intrauterine device, factors associated with discontinuation, and intrauterine device performance. We assessed the differences in continuation at discrete time points, pregnancy, and expulsion rates using χ2 tests and calculated hazard ratios

2017 American Journal of Obstetrics and Gynecology

164. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. (Abstract)

Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. To assess the endometrial response rates to treatment with the levonorgestrel intrauterine device in post-menopausal women with atypical hyperplasia/endometrial intraepithelial neoplasia and grade 1 endometrioid (AH/EC) endometrial carcinoma who are not surgical candidates.Chart review was undertaken of patients with AH/EC (...) who underwent levonorgestrel intrauterine device insertion by a gynecologic oncologist within two academic health systems between 2002 and 2013. When available, tissue blocks were evaluated with immunohistochemical staining for progesterone receptor expression.A total of 41 patients received treatment for AH/EC with the levonorgestrel intrauterine device. Follow up sufficient to assess response occurred in 36 women (88%). Complete response was documented in 18 of 36 women (50%), no response in 8

2017 Gynecologic Oncology

165. [Effectiveness research of medicated γ intrauterine device and medicated genefix intrauterine device inserted immediately after abortion]. (Abstract)

[Effectiveness research of medicated γ intrauterine device and medicated genefix intrauterine device inserted immediately after abortion]. To compare the effectiveness of medicated γ intrauterine device (IUD) and medicated genefix IUD inserted immediately after abortion.A multicenter clinical trail was performed for the study from Mar. 2012 to Jan. 2013. Totally 840 women who volunteered to participate were randomly allocated to γ-group (medicated γ IUD) or genefix-group (medicated genefix IUD

2016 Zhonghua fu chan ke za zhi Controlled trial quality: uncertain

166. Self-Administered Lidocaine Gel for Intrauterine Device Insertion in Nulliparous Women: A Randomized Controlled Trial (Abstract)

Self-Administered Lidocaine Gel for Intrauterine Device Insertion in Nulliparous Women: A Randomized Controlled Trial To evaluate self-administration of vaginal lidocaine gel to decrease pain with intrauterine device (IUD) insertion in nulliparous women.In this randomized, double-blind, placebo-controlled trial, women self-administered 2% lidocaine or placebo vaginal gel 5 minutes before IUD insertion. The primary outcome was change in pain from baseline to IUD insertion on a 100-mm visual

2016 EvidenceUpdates Controlled trial quality: predicted high

167. The Use of Hysteroscopy for the Diagnosis and Treatment of Intrauterine Pathology

intrauterine pathology such as endometrial polyps, uterine leiomyomas, uterine septa, retained products of pregnancy, and adhesions. Additional uses of operative hysteroscopy include the removal of foreign bodies such as malpositioned intrauterine devices, tubal cannulation, treatment of isthmoceles, and directed biopsy. Hysteroscopic Polypectomy and Myomectomy Indications for polyp removal include abnormal uterine bleeding, infertility, and recurrent pregnancy loss. Management of endometrial polyps (...) hysteroscopy than during diagnostic hysteroscopy (0.95% versus 0.13%; P <.01). See for potential complications, incidence, and risk factors. Box 1. Situations When Hysteroscopy May Be Used* † Removal of foreign bodies (eg, intrauterine devices with nonvisualized strings or intrauterine devices that are malpositioned) Diagnosis and treatment of intrauterine adhesions Correction of septate uteri Detection of malignancy Management of cesarean scar pregnancy Management of retained products of pregnancy

2020 American College of Obstetricians and Gynecologists

168. FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions

FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions FSRH CEU recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions - Faculty of Sexual and Reproductive Healthcare Privacy notice We would like to set cookies on your device as described in our . If you're OK with this then please accept and continue. Alternatively you (...) , to reduce risk of coronavirus transmission, non-essential face-to-face contact with healthcare providers is being minimised where possible. Replacement procedures for long-acting reversible contraceptive (LARC) devices that have recently expired are non-essential. This FSRH CEU statement provides recommendation on extended use of the etonogestrel implant and 52mg levonorgestrel-releasing intrauterine system during COVID restrictions. Your download should start automatically. If not . About FSRH FSRH

2020 Faculty of Sexual & Reproductive Healthcare

169. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Full Text available with Trip Pro

Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. The objective was to measure the rate of unintended pregnancies in women using levonorgestrel-releasing intrauterine systems (LNG IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) in a typical population of IUD users and to describe associated complications.A multinational, prospective, non-interventional

2015 Contraception

170. Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. Full Text available with Trip Pro

Risk of Uterine Perforation with Levonorgestrel-Releasing and Copper Intrauterine Devices in the European Active Surveillance Study on Intrauterine Devices. The objectives were to identify and compare the incidence of uterine perforation and other medically adverse events associated with levonorgestrel-releasing intrauterine systems (LNG-IUSs, releasing 20 mcg LNG daily) and copper intrauterine devices (IUDs) under routine conditions of use in a study population representative of typical (...) -three of the total 81 perforations were associated with previously suspected risk factors (e.g., breastfeeding, time since last delivery ≤36 weeks). No perforations led to serious illness or to injury of intra-abdominal or pelvic structures.Uterine perforation incidence in this study was low, with a benign clinical course thereafter. The LNG-IUSs and copper IUDs did not have clinically important differences in perforation rates.The European Active Surveillance Study on Intrauterine Devices

2015 Contraception

171. Intrauterine Device

Intrauterine Device Intrauterine Device Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intrauterine Device Intrauterine Device Aka (...) : Intrauterine Device , IUD , Paragard , Copper T-380A IUD , Progestasert , Mirena , Skyla , Liletta From Related Chapters II. Contraindications: Absolute Undiagnosed Uterine abnormality that distorts endometrial cavity Current intrauterine infection Unresolved abnormal Current endometrial or Findings suggestive of trophoblastic disease or copper allergy (Copper-T IUD) Uterine or pelvic infection within last 3 months III. Contraindications: Historical that are no longer contraindications (restrictions

2018 FP Notebook

172. Intrauterine Device Insertion

Intrauterine Device Insertion Intrauterine Device Insertion Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Intrauterine Device (...) Insertion Intrauterine Device Insertion Aka: Intrauterine Device Insertion , IUD Placement , Difficult IUD Removal , Missing IUD Strings II. Preparation See Contraindications Adverse effects Infection risk reduction Screen for and before placing Antibiotic prophylaxis is not indicated Not indicated for routine prevention Not indicated for Pretreatment Previously ( ) was recommended prior to IUD insertion to make the insertion easier No longer recommended due to no benefit in recent trials and risk

2018 FP Notebook

173. Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial Full Text available with Trip Pro

Ketorolac for Pain Control With Intrauterine Device Placement: A Randomized Controlled Trial To evaluate intramuscular ketorolac compared with placebo saline injection for pain control with intrauterine device (IUD) placement.We conducted a randomized, double-blind, placebo-controlled trial between July 2012 and March 2014. Patients received 30 mg ketorolac or placebo saline intramuscular injection 30 minutes before IUD placement. The primary outcome was pain with IUD placement on a 10-cm

2015 EvidenceUpdates Controlled trial quality: predicted high

174. Conservative management of stage 1 endometrial adenocarcinoma with weight loss +/- metformin +/- levonorgestrel intrauterine device: a systematic review

Conservative management of stage 1 endometrial adenocarcinoma with weight loss +/- metformin +/- levonorgestrel intrauterine device: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2018 PROSPERO

175. Hysteroscopic removal of intrauterine devices with no visible strings in early desired pregnancy: a systematic review of the current evidence

Hysteroscopic removal of intrauterine devices with no visible strings in early desired pregnancy: a systematic review of the current evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

176. Removal of intrauterine devices in women with pelvic inflammatory disease: a systematic review and meta-analysis

Removal of intrauterine devices in women with pelvic inflammatory disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

177. Comparison of the efficacy and safety of 10 commonly used intrauterine devices in China: a network meta-analysis

Comparison of the efficacy and safety of 10 commonly used intrauterine devices in China: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

178. Comparing the Efficacy of Intrauterine Balloon and Intrauterine Contraceptive Device for the Therapy of Uterine Adhesion

Comparing the Efficacy of Intrauterine Balloon and Intrauterine Contraceptive Device for the Therapy of Uterine Adhesion Comparing the Efficacy of Intrauterine Balloon and Intrauterine Contraceptive Device for the Therapy of Uterine Adhesion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Comparing the Efficacy of Intrauterine Balloon and Intrauterine Contraceptive Device for the Therapy of Uterine Adhesion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02867202 Recruitment Status : Unknown Verified

2016 Clinical Trials

179. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception. (Abstract)

Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception. The aim of this study was to compare the safety, bleeding pattern, effects, side-effects, complications and 6-month continuity rates of levonorgestrel-bearing intrauterine system (LNG-IUS) with conventional copper intrauterine device (Cu-IUD) inserted immediately after voluntary termination of pregnancy up to 10 weeks of gestation.One hundred women who underwent voluntary (...) %, respectively. In LNG-IUS users, the incidence of amenorrhea and the number of spotting days were higher and hemoglobin increased throughout the follow-up period. The side-effects related to both methods were not different from interval insertions.Immediate post-abortion intrauterine contraception with Cu-IUD or LNG-IUS is a safe, reliable method. The incidence of side-effects is similar, and there is only a slightly higher rate of expulsion but an acceptable rate of method continuation.© 2015 Japan Society

2016 The journal of obstetrics and gynaecology research Controlled trial quality: uncertain

180. Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion

Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02769247 Recruitment Status : Completed First Posted : May 11, 2016 Results First Posted : November 8, 2018

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>